Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and maintenance pembrolizumab for resectable head and neck mucosal melanoma
2017-001628-23Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in mucosal melanoma (MM), sponsored by Gustave Roussy. Primary endpoint: Disease-free survival. Started Oct 2017; status: active.
02
Drugs
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on 2017-001628-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001628-23.